856 related articles for article (PubMed ID: 19843296)
21. Steroid avoidance with early intensified dosing of enteric-coated mycophenolate sodium: a randomized multicentre trial in kidney transplant recipients.
Thierry A; Mourad G; Büchler M; Kamar N; Villemain F; Heng AE; Le Meur Y; Choukroun G; Toupance O; Legendre C; Lepogamp P; Kessler M; Merville P; Moulin B; Quéré S; Terpereau A; Chaouche-Teyara K; Touchard G
Nephrol Dial Transplant; 2012 Sep; 27(9):3651-9. PubMed ID: 22645323
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
23. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
Triemer HL; Pearson TC; Odom KL; Larsen CP
Clin Transplant; 2000 Aug; 14(4 Pt 2):413-20. PubMed ID: 10946781
[TBL] [Abstract][Full Text] [Related]
24. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes.
Barsoum RS; Morsey AA; Iskander IR; Morgan MM; Fayad TM; Atalla NT; Wafik H; Grace RA; Adel N; Khalil SS
Exp Clin Transplant; 2007 Dec; 5(2):649-57. PubMed ID: 18194116
[TBL] [Abstract][Full Text] [Related]
25. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
Wiesel M; Carl S
J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
[TBL] [Abstract][Full Text] [Related]
26. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
Cantarovich D
J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
[TBL] [Abstract][Full Text] [Related]
27. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
28. Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
Chadban S; Eris J; Russ G; Campbell S; Chapman J; Pussell B; Trevillian P; Ierino F; Thomson N; Hutchison B; Irish A; Woodcock C; Kurstjens N; Walker R;
Nephrology (Carlton); 2013 Jan; 18(1):63-70. PubMed ID: 23110508
[TBL] [Abstract][Full Text] [Related]
29. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.
Wiesner R; Rabkin J; Klintmalm G; McDiarmid S; Langnas A; Punch J; McMaster P; Kalayoglu M; Levy G; Freeman R; Bismuth H; Neuhaus P; Mamelok R; Wang W
Liver Transpl; 2001 May; 7(5):442-50. PubMed ID: 11349266
[TBL] [Abstract][Full Text] [Related]
30. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.
Etienne I; Toupance O; Bénichou J; Thierry A; Al Najjar A; Hurault de Ligny B; Le Meur Y; Westeel PF; Marquet P; François A; Hellot MF; Godin M
Nephrol Dial Transplant; 2010 Sep; 25(9):3096-106. PubMed ID: 20299336
[TBL] [Abstract][Full Text] [Related]
31. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
32. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
33. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
34. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
Cai L; Zeng F; Liu B; Wei L; Chen Z; Jiang J
Int J Clin Pract Suppl; 2014 Apr; (181):23-30. PubMed ID: 24673716
[TBL] [Abstract][Full Text] [Related]
35. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.
Le Meur Y; Thierry A; Glowacki F; Rerolle JP; Garrigue V; Ouali N; Heng AE; Delahousse M; Albano L; Lang P; Couzi L; Jaureguy M; Lebranchu Y; Mousson C; Glotz D; Kessler M; Vrtovsnik F; Rouanet S; Tagieva N; Kamar N
Transplantation; 2011 Dec; 92(11):1244-51. PubMed ID: 22067312
[TBL] [Abstract][Full Text] [Related]
36. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
37. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
[TBL] [Abstract][Full Text] [Related]
39. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
[TBL] [Abstract][Full Text] [Related]
40. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]